News

AgeX Therapeutics, Inc. and ImStem Biotechnology, Inc. announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s…
Read More...

FSD Pharma Inc. announced that the U.S. Food and Drug Administration (FDA) has given the company permission to submit an Investigational New Drug Application (IND) for the use of…
Read More...

PharmAbcine announced that the company entered into a license agreement with Wincal Biopharm, a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the commercial value…
Read More...

Bristol Myers Squibb announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with…
Read More...

Predictive Oncology Inc. announced that it has completed the acquisition of the assets of Soluble Therapeutics, Inc. and BioDtech, Inc., each of which is a wholly-owned subsidiary of…
Read More...

Codiak BioSciences, Inc., a company at the forefront of advancing engineered exosomes as a new class of biologic medicines, announced that it has entered into two strategic…
Read More...

AVEO Oncology announced that the U.S. Food and Drug Administration (FDA) accepted for filing its New Drug Application (NDA) seeking approval for tivozanib, the Company’s next-generation…
Read More...

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most…
Read More...

AstraZeneca and MSD Inc., Kenilworth, N.J., US announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line…
Read More...

Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. announced an expansion of their existing collaboration to provide Regeneron with rights to develop products for…
Read More...

AbbVie and Jacobio Pharmaceuticals announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. SHP2 …
Read More...

Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, announced the closing of an…
Read More...

Innovent Biologics, Inc. jointly announced with Eli Lilly and Company (Lilly) the research results of TYVYT (sintilimab injection) ORIENT-1 study for the treatment of relapsed or…
Read More...

Celltrion Group announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the…
Read More...

Ajinomoto Bio-Pharma Services announced that it has entered into a manufacturing agreement with Humanigen, Inc., for the fill finish supply of lenzilumab, currently being studied in a…
Read More...

Roche announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the…
Read More...

Almac Group has received a $288,000 grant to support a clinical study in Sub-Saharan Africa in efforts to find a treatment for Coronavirus. This was awarded from the COVID-19…
Read More...

Lonza Sales AG, through its Bioscience Division, and Sanquin Reagents B.V. have entered into a strategic partnership for the commercialization of a range of specialized reagents for…
Read More...

Bird Rock Bio, Inc., a clinical stage biopharmaceutical company, announced that the Company has filed an investigational new drug (IND) application with the U.S. Food and Drug…
Read More...

Advent Srl, an IRBM company and global leader in viral vector manufacturing, announces it has manufactured 13,000 doses of the novel Covid-19 vaccine candidate, ChAdOx1 nCoV-19 (now…
Read More...